证券记录 · 已归档季度
NBIX
Neurocrine Biosciences, Inc. · Healthcare · Biotechnology
18被追踪持有人
0Δ持有人
22.97M持有股份
$2.54B报告持仓市值
+1新建仓位
−1清仓
动量输入(同类管理人): 持有人广度 0.0% · 股份流向 +7.0% · 净新建仓位 0.0% · 公式
所有持股数据:仅限已追踪的 13F 管理人,普通股持仓,报告期 Q1 2025
持股变化趋势
| 季度 | 持有人 | Δ | 股份 | 报告持仓市值 | 新增 | 清仓 |
|---|---|---|---|---|---|---|
| Q3 2026 | 5 | -1 | 774.42K | $108.76M | n/a | −1 |
| Q2 2026 | 154 | 0 | 76.05M | $12.81B | +5 | −4 |
| Q1 2026 | 156 | 0 | 77.10M | $10.14B | +6 | −7 |
| Q4 2025 | 155 | 0 | 77.25M | $10.95B | +1 | n/a |
| Q3 2025 | 22 | 0 | 59.57M | $8.36B | +1 | −2 |
| Q2 2025 | 20 | -1 | 49.44M | $6.21B | +2 | −3 |
| Q1 2025 | 18 | 0 | 22.97M | $2.54B | +1 | −1 |
| Q4 2024 | 18 | 0 | 21.48M | $2.93B | +1 | −1 |
| Q3 2024 | 17 | 0 | 13.43M | $1.55B | n/a | n/a |
| Q2 2024 | 17 | n/a | 11.91M | $1.64B | n/a | n/a |
持有人 · Q1 2025
| # | 管理人 | 股份 | Δ股份 | 价值 | 其权重 | 持有 | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Dodge & Cox ✦ | 5.53M | +83.5% | $612.13M | 0.3% | ▲ Add | 4 | SEC ↗ |
| 2 | State Street Global Advisors ✦ (被动) | 4.86M | -0.6% | $537.75M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 3 | Renaissance Technologies ✦ | 2.50M | +0.5% | $276.80M | 0.4% | ▲ Add | 4 | SEC ↗ |
| 4 | Wellington Management ✦ | 2.10M | +44.0% | $232.04M | 0.0% | ▲ Add | 4 | SEC ↗ ×6 |
| 5 | Geode Capital Management ✦ (被动) | 1.97M | +5.0% | $217.41M | 0.0% | ▲ Add | 4 | SEC ↗ ×2 |
| 6 | T. Rowe Price ✦ | 1.54M | +3.3% | $170.28M | 0.0% | ▲ Add | 4 | SEC ↗ ×2 |
| 7 | AQR Capital Management ✦ | 1.07M | -43.4% | $118.85M | 0.1% | ▼ Trim | 4 | SEC ↗ ×7 |
| 8 | Norges Bank ✦ (被动) | 999.82K | +207.4% | $110.58M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 9 | Citadel Advisors ✦ | 889.03K | -65.0% | $98.33M | 0.1% | ▼ Trim | 4 | SEC ↗ |
| 10 | Millennium Management ✦ | 576.59K | +37.7% | $63.77M | 0.1% | ▲ Add | 4 | SEC ↗ |
| 11 | PRIMECAP Management ✦ | 382.44K | -2.9% | $42.30M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 12 | Soros Fund Management ✦ | 239.82K | +19.9% | $26.52M | 0.7% | ▲ Add | 4 | SEC ↗ |
| 13 | Fisher Asset Management ✦ | 95.26K | +3.4% | $10.54M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 14 | Bridgewater Associates ✦ | 87.24K | -73.8% | $9.65M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 15 | Arrowstreet Capital ✦ | 66.60K | 新增 | $7.37M | 0.0% | New | 1 | SEC ↗ |
| 16 | Gotham Asset Management ✦ | 31.02K | +442.9% | $3.43M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 17 | D. E. Shaw & Co. ✦ | 14.59K | -49.2% | $1.61M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 18 | Two Sigma Investments ✦ | 10.20K | -61.9% | $1.13M | 0.0% | ▼ Trim | 4 | SEC ↗ |
"持仓权重"指该仓位占该管理人13F申报股票组合市值的比例,即持仓信心指标。✦ = 精选管理人。
新增买入方
| Arrowstreet Capital | $7.37M | 0.0% |
已清仓
| Marshall Wace | $331,013 | 曾为 0.0% |
全市场背景: 涵盖所有13F申报机构(SEC结构化数据, Q1 2026): 690 持有人, 94.09M 股份, $12.08B 已申报. 这是与上方被追踪全域数据不同的较早期间,两者从不混用。
常见共同持仓
持有该证券的受追踪机构最常同时持有的其他证券:基于共同持有计数,而非基本面关联。
公开市场买入 (P)
在我们的覆盖窗口内无内部人士公开市场买入记录。
公开市场卖出 (S)
Sep 14
Boyer David W.
Officer · 826 股 · $130,051
Sep 14
ABERNETHY MATT
Officer · 2.31K 股 · $363,285
Sep 09
BENEVICH ERIC
Officer · 2.15K 股 · $333,030
授予、行权及税务代扣代缴在本平台均不计入买入或卖出。 方法论
Oct 15
SC 13G/A: JPMORGAN CHASE & CO
Jul 27
SC 13G/A: JPMORGAN CHASE & CO
数据来源: 持股数据来源于已解析的13F普通股持仓(被追踪范围,变动对比集);内部人行为来自Form 3/4/5;重大持股来自Schedule 13D/13G;所有文件均链接至SEC EDGAR原始申报。
报告期: Q1 2025 ·
方法论 ·
通过API获取此数据